Stereotaxis to Report First Quarter 2021 Financial Results on May 10, 2021
Stereotaxis (NYSE: STXS) is set to release its first quarter 2021 financial results on May 10, 2021, before the U.S. markets open. A conference call will follow at 10 a.m. EST to discuss the results and corporate developments. Investors can access the call via dial-in or through a webcast available on the Stereotaxis investor relations website. The company focuses on innovative robotic technologies for cardiac arrhythmia treatment, aiming to enhance patient care with precision and safety.
- Scheduled financial results release may indicate transparency and commitment to investors.
- Hosting a conference call suggests active engagement with stakeholders.
- None.
ST. LOUIS, April 19, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 first quarter on Monday, May 10, 2021 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis first quarter 2021 financial results conference call | |
| When: | Monday, May 10, 2021 at 10:00 a.m. EST (7:00 a.m. PST) | |
| Dial In Number: | To access the live call, dial 800-367-2403 (US and Canada) or 334-777-6978 (International) and give the participant pass code 6657929. | |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/ | |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately two hours following the end of the call through June 10, 2021. To request access for a replay of the conference call, please Click Here. | |
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
FAQ
When will Stereotaxis release its Q1 2021 financial results?
What time is the Stereotaxis Q1 2021 earnings conference call?
How can I access the Stereotaxis earnings call?
Where can I find the webcast for the Stereotaxis earnings call?
